Open Payments

JAMES M. MCCARTY

Type
Physician · Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases
Where
MADERA, CA
NPI
1598777500
Received
$1,787,860 in 474 records, 2019 to 2025 ($877,181 general, $910,678 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment11$47,122
2025Research payment17$160,641
2024General payment1$955
2024Research payment19$102,987
2023General payment50$203,333
2023Research payment23$125,650
2022General payment88$218,015
2022Research payment47$215,687
2021General payment61$209,887
2021Research payment61$145,762
2020General payment35$155,067
2020Research payment50$159,950
2019General payment11$42,800

By company

CompanyRecordsAmountYears
Emergent BioSolutions Inc.460$1,700,3832019–2025
Bavarian Nordic A/S14$87,4762023–2024

By nature of payment

NatureRecordsAmount
Research payment217$910,678
Consulting Fee228$859,854
Travel and Lodging21$14,163
Compensation for services other than consulting, including serving as faculty or as a speaker at a v3$2,668
Food and Beverage5$495

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-17Emergent BioSolutions Inc.$14,612Consulting FeeCash or cash equivalentACAM2000 Drug, Smallpox2025
2025-12-17Emergent BioSolutions Inc.$4,987Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2025
2025-11-19Emergent BioSolutions Inc.$16,012Consulting FeeCash or cash equivalentACAM2000 Drug, Smallpox2025
2025-11-19Emergent BioSolutions Inc.$3,412Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2025
2025-10-23Emergent BioSolutions Inc.$9,887Consulting FeeCash or cash equivalentACAM2000 Drug, Smallpox2025
2025-10-23Emergent BioSolutions Inc.$8,837Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2025
2025-09-17Emergent BioSolutions Inc.$19,862Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2025
2025-09-17Emergent BioSolutions Inc.$2,012Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2025
2025-08-20Emergent BioSolutions Inc.$13,475Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2025
2025-08-20Emergent BioSolutions Inc.$3,937Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2025
2025-07-16Emergent BioSolutions Inc.$6,387Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2025
2025-07-16Emergent BioSolutions Inc.$3,587Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2025
2025-06-18Emergent BioSolutions Inc.$9,975Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2025
2025-06-18Emergent BioSolutions Inc.$437Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2025
2025-06-04Emergent BioSolutions Inc.$5,337Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2025
2025-06-04Emergent BioSolutions Inc.$4,558Consulting FeeCash or cash equivalent2025
2025-06-04Emergent BioSolutions Inc.$778Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2025
2025-04-29Emergent BioSolutions Inc.$1,400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-04-29Emergent BioSolutions Inc.$277Travel and LodgingCash or cash equivalent2025
2025-04-29Emergent BioSolutions Inc.$158Travel and LodgingCash or cash equivalent2025
2025-04-29Emergent BioSolutions Inc.$78Travel and LodgingCash or cash equivalent2025
2025-04-29Emergent BioSolutions Inc.$76Travel and LodgingCash or cash equivalent2025
2025-04-29Emergent BioSolutions Inc.$32Travel and LodgingCash or cash equivalent2025
2025-04-29Emergent BioSolutions Inc.$27Travel and LodgingCash or cash equivalent2025
2025-04-16Emergent BioSolutions Inc.$18,375Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2025
2025-03-19Emergent BioSolutions Inc.$24,850Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2025
2025-02-19Emergent BioSolutions Inc.$16,537Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2025
2025-01-15Emergent BioSolutions Inc.$17,850Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2025
2024-12-18Emergent BioSolutions Inc.$13,650Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-11-20Emergent BioSolutions Inc.$11,287Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-10-16Emergent BioSolutions Inc.$8,575Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-08-21Emergent BioSolutions Inc.$2,887Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-08-21Emergent BioSolutions Inc.$2,012Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2024
2024-07-17Emergent BioSolutions Inc.$10,500Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-07-17Emergent BioSolutions Inc.$7,350Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2024
2024-07-03Emergent BioSolutions Inc.$10,762Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-07-03Emergent BioSolutions Inc.$5,250Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2024
2024-05-22Emergent BioSolutions Inc.$8,400Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-05-22Emergent BioSolutions Inc.$612Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2024
2024-04-17Emergent BioSolutions Inc.$1,312Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-04-17Emergent BioSolutions Inc.$612Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2024
2024-03-20Emergent BioSolutions Inc.$5,250Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-03-20Emergent BioSolutions Inc.$962Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2024
2024-02-21Emergent BioSolutions Inc.$6,125Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2024-02-21Emergent BioSolutions Inc.$1,662Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2024
2024-01-19Bavarian Nordic A/S$955Consulting FeeCash or cash equivalent2024
2024-01-17Emergent BioSolutions Inc.$3,675Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2024
2024-01-17Emergent BioSolutions Inc.$2,100Research paymentCash or cash equivalentTEMBEXA Drug, Purine nucleosidesStudy Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)2024
2023-12-20Emergent BioSolutions Inc.$2,712Research paymentCash or cash equivalentTembexa Drug, Purine nucleosidesTMBX2023
2023-12-06Emergent BioSolutions Inc.$4,550Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-11-15Emergent BioSolutions Inc.$12,687Research paymentCash or cash equivalentTembexa Drug, Purine nucleosidesTMBX2023
2023-11-08Emergent BioSolutions Inc.$17,325Research paymentCash or cash equivalentTembexa Drug, Purine nucleosidesTMBX2023
2023-11-02Emergent BioSolutions Inc.$1,837Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-11-01Bavarian Nordic A/S$6,300Consulting FeeCash or cash equivalent2023
2023-10-26Bavarian Nordic A/S$2,001Travel and LodgingCash or cash equivalent2023
2023-10-26Bavarian Nordic A/S$105Consulting FeeCash or cash equivalent2023
2023-10-26Bavarian Nordic A/S$9Food and BeverageCash or cash equivalent2023
2023-10-04Emergent BioSolutions Inc.$11,987Research paymentCash or cash equivalentTembexa Drug, Purine nucleosidesTMBX2023
2023-10-04Emergent BioSolutions Inc.$2,275Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-10-01Bavarian Nordic A/S$2,800Consulting FeeCash or cash equivalent2023
2023-09-06Emergent BioSolutions Inc.$8,487Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-09-01Bavarian Nordic A/S$5,075Consulting FeeCash or cash equivalent2023
2023-08-30Bavarian Nordic A/S$20,737Consulting FeeCash or cash equivalent2023
2023-08-30Bavarian Nordic A/S$612Consulting FeeCash or cash equivalent2023
2023-08-30Emergent BioSolutions Inc.$612Research paymentCash or cash equivalentTembexa Drug, Purine nucleosidesTMBX2023
2023-08-30Bavarian Nordic A/S$612Consulting FeeCash or cash equivalent2023
2023-08-23Emergent BioSolutions Inc.$16,275Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-08-16Bavarian Nordic A/S$20,912Consulting FeeCash or cash equivalent2023
2023-08-16Bavarian Nordic A/S$3,675Consulting FeeCash or cash equivalent2023
2023-07-31Bavarian Nordic A/S$12,512Consulting FeeCash or cash equivalent2023
2023-07-05Emergent BioSolutions Inc.$5,775Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-06-14Bavarian Nordic A/S$11,168Consulting FeeCash or cash equivalent2023
2023-05-31Emergent BioSolutions Inc.$4,550Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-05-03Emergent BioSolutions Inc.$6,650Research paymentCash or cash equivalentA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172023
2023-05-03Emergent BioSolutions Inc.$6,037Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-05-03Emergent BioSolutions Inc.$3,937Consulting FeeCash or cash equivalent2023
2023-05-03Emergent BioSolutions Inc.$3,937Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-05-03Emergent BioSolutions Inc.$3,325Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-05-03Emergent BioSolutions Inc.$3,150Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-05-03Emergent BioSolutions Inc.$3,150Consulting FeeCash or cash equivalent2023
2023-05-03Emergent BioSolutions Inc.$3,062Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-05-03Emergent BioSolutions Inc.$2,275Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-05-03Emergent BioSolutions Inc.$2,100Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2023
2023-05-03Emergent BioSolutions Inc.$1,137Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-05-03Emergent BioSolutions Inc.$1,137Research paymentCash or cash equivalentA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172023
2023-04-05Emergent BioSolutions Inc.$8,050Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-04-05Emergent BioSolutions Inc.$5,250Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-04-05Emergent BioSolutions Inc.$4,550Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-04-05Emergent BioSolutions Inc.$4,112Consulting FeeCash or cash equivalent2023
2023-04-05Emergent BioSolutions Inc.$3,237Research paymentCash or cash equivalentA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172023
2023-04-05Emergent BioSolutions Inc.$3,150Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-04-05Emergent BioSolutions Inc.$2,800Research paymentCash or cash equivalentA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172023
2023-04-05Emergent BioSolutions Inc.$2,800Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-04-05Emergent BioSolutions Inc.$2,537Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2023
2023-04-05Emergent BioSolutions Inc.$1,925Consulting FeeCash or cash equivalent2023
2023-04-05Emergent BioSolutions Inc.$700Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-04-05Emergent BioSolutions Inc.$87Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-04-05Emergent BioSolutions Inc.$87Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-03-02Emergent BioSolutions Inc.$11,025Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-03-02Emergent BioSolutions Inc.$5,425Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2023
2023-03-02Emergent BioSolutions Inc.$4,637Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-03-02Emergent BioSolutions Inc.$4,550Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-03-02Emergent BioSolutions Inc.$4,375Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-03-02Emergent BioSolutions Inc.$3,850Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-03-02Emergent BioSolutions Inc.$1,750Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-03-02Emergent BioSolutions Inc.$1,312Research paymentCash or cash equivalentA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172023
2023-03-02Emergent BioSolutions Inc.$1,137Research paymentCash or cash equivalentA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172023
2023-03-02Emergent BioSolutions Inc.$700Consulting FeeCash or cash equivalent2023
2023-03-02Emergent BioSolutions Inc.$87Consulting FeeCash or cash equivalent2023
2023-02-22Emergent BioSolutions Inc.$9,100Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-02-22Emergent BioSolutions Inc.$4,812Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-02-22Emergent BioSolutions Inc.$2,975Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-02-22Emergent BioSolutions Inc.$2,362Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-02-22Emergent BioSolutions Inc.$2,275Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-02-22Emergent BioSolutions Inc.$2,012Research paymentCash or cash equivalentA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172023
2023-02-22Emergent BioSolutions Inc.$875Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-02-22Emergent BioSolutions Inc.$700Consulting FeeCash or cash equivalent2023
2023-02-22Emergent BioSolutions Inc.$700Consulting FeeCash or cash equivalent2023
2023-02-22Emergent BioSolutions Inc.$87Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2023
2023-02-02Emergent BioSolutions Inc.$5,862Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2023
2023-01-25Emergent BioSolutions Inc.$3,587Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2023
2022-12-14Emergent BioSolutions Inc.$10,587Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-12-14Emergent BioSolutions Inc.$6,037Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-12-14Emergent BioSolutions Inc.$4,900Consulting FeeCash or cash equivalent2022
2022-12-14Emergent BioSolutions Inc.$4,287Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2022
2022-12-14Emergent BioSolutions Inc.$3,237Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-12-14Emergent BioSolutions Inc.$2,975Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2022
2022-12-14Emergent BioSolutions Inc.$2,012Research paymentCash or cash equivalentVaxchora Drug, Cholera VaccineA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-12-14Emergent BioSolutions Inc.$1,575Consulting FeeCash or cash equivalent2022
2022-12-14Emergent BioSolutions Inc.$1,400Research paymentCash or cash equivalentChikungunyaA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-12-14Emergent BioSolutions Inc.$525Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-12-14Emergent BioSolutions Inc.$87Research paymentCash or cash equivalentChikungunyaA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-12-11Emergent BioSolutions Inc.$8,137Research paymentCash or cash equivalentChikungunyaA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-12-11Emergent BioSolutions Inc.$4,025Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-12-11Emergent BioSolutions Inc.$3,937Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-12-11Emergent BioSolutions Inc.$2,450Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-12-11Emergent BioSolutions Inc.$1,750Consulting FeeCash or cash equivalent2022
2022-12-11Emergent BioSolutions Inc.$1,312Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-12-11Emergent BioSolutions Inc.$962Research paymentCash or cash equivalentVaxchora Drug, Cholera VaccineA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-12-11Emergent BioSolutions Inc.$910Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-12-11Emergent BioSolutions Inc.$815Travel and LodgingCash or cash equivalent2022
2022-12-11Emergent BioSolutions Inc.$511Travel and LodgingCash or cash equivalent2022
2022-12-11Emergent BioSolutions Inc.$87Research paymentCash or cash equivalentChikungunyaEBSI-CV-317-004: A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX032022
2022-12-11Emergent BioSolutions Inc.$65Travel and LodgingCash or cash equivalent2022
2022-12-11Emergent BioSolutions Inc.$59Travel and LodgingCash or cash equivalent2022
2022-11-23Emergent BioSolutions Inc.$5,337Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2022
2022-11-23Emergent BioSolutions Inc.$3,937Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2022
2022-11-07Emergent BioSolutions Inc.$150Food and BeverageIn-kind items and services2022
2022-10-26Emergent BioSolutions Inc.$6,212Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-10-26Emergent BioSolutions Inc.$5,687Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2022
2022-10-26Emergent BioSolutions Inc.$5,687Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2022
2022-10-26Emergent BioSolutions Inc.$5,250Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-10-26Emergent BioSolutions Inc.$3,850Consulting FeeCash or cash equivalent2022
2022-10-26Emergent BioSolutions Inc.$3,325Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-10-26Emergent BioSolutions Inc.$2,800Research paymentCash or cash equivalentVaxchora Drug, Cholera VaccineA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-10-26Emergent BioSolutions Inc.$1,925Research paymentCash or cash equivalentChikungunyaEBSI-CV-317-002: A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of an Alum-Adjuvanted Chikungunya Vi2022
2022-10-26Emergent BioSolutions Inc.$1,050Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-10-26Emergent BioSolutions Inc.$262Research paymentCash or cash equivalentChikungunyaA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-10-05Emergent BioSolutions Inc.$9,450Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2022
2022-10-05Emergent BioSolutions Inc.$5,425Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2022
2022-10-05Emergent BioSolutions Inc.$4,637Research paymentCash or cash equivalentChikungunyaA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-10-05Emergent BioSolutions Inc.$3,587Consulting FeeCash or cash equivalent2022
2022-10-05Emergent BioSolutions Inc.$2,887Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-10-05Emergent BioSolutions Inc.$2,800Research paymentCash or cash equivalentVaxchora Drug, Cholera VaccineA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-10-05Emergent BioSolutions Inc.$2,712Research paymentCash or cash equivalentChikungunyaEBSI-CV-317-004: A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX032022
2022-10-05Emergent BioSolutions Inc.$2,712Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-10-05Emergent BioSolutions Inc.$612Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-10-05Emergent BioSolutions Inc.$87Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-08-31Emergent BioSolutions Inc.$6,650Research paymentCash or cash equivalentChikungunyaA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-08-31Emergent BioSolutions Inc.$4,550Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-08-31Emergent BioSolutions Inc.$3,587Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-08-31Emergent BioSolutions Inc.$3,150Consulting FeeCash or cash equivalent2022
2022-08-31Emergent BioSolutions Inc.$2,537Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-08-31Emergent BioSolutions Inc.$962Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-08-31Emergent BioSolutions Inc.$175Research paymentCash or cash equivalentVaxchora Drug, Cholera VaccinePhase 4 Placebo Controlled Study to Assess the Safety and Immunogenicity of Vaxchora (Cholera Vaccine, Live, Oral) in In2022
2022-08-24Emergent BioSolutions Inc.$10,500Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2022
2022-08-24Emergent BioSolutions Inc.$2,800Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2022
2022-07-27Emergent BioSolutions Inc.$12,512Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2022
2022-07-27Emergent BioSolutions Inc.$4,200Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2022
2022-07-27Emergent BioSolutions Inc.$3,850Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-07-27Emergent BioSolutions Inc.$3,587Research paymentCash or cash equivalentChikungunyaA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-07-27Emergent BioSolutions Inc.$3,500Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-07-27Emergent BioSolutions Inc.$3,237Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-07-27Emergent BioSolutions Inc.$3,062Research paymentCash or cash equivalentChikungunyaA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-07-27Emergent BioSolutions Inc.$1,837Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-07-27Emergent BioSolutions Inc.$612Research paymentCash or cash equivalentVaxchora Drug, Cholera VaccineA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-07-27Emergent BioSolutions Inc.$437Consulting FeeCash or cash equivalent2022
2022-07-13Emergent BioSolutions Inc.$5,485Travel and LodgingCash or cash equivalent2022
2022-07-13Emergent BioSolutions Inc.$1,180Travel and LodgingCash or cash equivalent2022
2022-07-13Emergent BioSolutions Inc.$358Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-07-13Emergent BioSolutions Inc.$80Travel and LodgingCash or cash equivalent2022
2022-07-13Emergent BioSolutions Inc.$45Travel and LodgingCash or cash equivalent2022
2022-07-06Emergent BioSolutions Inc.$13,125Research paymentCash or cash equivalentUniversal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)2022
2022-07-06Emergent BioSolutions Inc.$5,862Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-07-06Emergent BioSolutions Inc.$4,025Consulting FeeCash or cash equivalentVaxchora Drug, Cholera Vaccine2022
2022-07-06Emergent BioSolutions Inc.$3,850Consulting FeeCash or cash equivalent2022
2022-07-06Emergent BioSolutions Inc.$3,062Research paymentCash or cash equivalentChikungunyaA Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX03172022
2022-07-06Emergent BioSolutions Inc.$2,100Consulting FeeCash or cash equivalentVivotif Drug, Salmonella Typhi2022
2022-07-06Emergent BioSolutions Inc.$1,532Travel and LodgingCash or cash equivalent2022
2022-07-06Emergent BioSolutions Inc.$1,498Travel and LodgingCash or cash equivalent2022

The latest 200 records of 474.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Madera CountyMadera city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Madera, CA, county Madera County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Madera, CA
County
Madera County, CA
State
California
Population B0100367,831160,94039,287,377
Population, 2020 census P166,224156,25539,538,223
Median age B0100230.434.637.9
Under 18 B0100130.8%27.1%22.0%
65 and over B010019.6%14.4%15.7%
Households B1100117,52645,37913,548,091
Foreign born B0500225.6%20.1%27.0%
Median household income B19013$63,933$76,627$99,122
Median family income B19113$67,479$83,389$113,346
Per capita income B19301$24,200$30,077$49,513
Poverty rate B1700125.6%19.2%12.0%
Unemployment rate B2302512.6%10.1%6.6%
Civilian labor force B2302529,99769,01220,068,466
Mean commute (minutes) B0801325.727.928.7
Bachelor's degree or higher B1500310.9%17.9%37.1%
Housing units B2500118,56251,01514,644,735
Owner-occupied B2500354.7%67.5%55.9%
Renters B2500345.3%32.5%44.1%
Median home value B25077$359,900$393,200$734,700
Median gross rent B25064$1,353$1,390$2,036
White, not Hispanic B0300212.2%29.9%33.8%
Black B030022.9%2.4%5.2%
Hispanic or Latino B0300281.1%60.9%40.2%
Asian B030021.3%2.4%15.3%
American Indian and Alaska Native B030020.1%0.4%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Madera, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.